CAPN3 and limb-girdle muscular dystrophy: With the exception of countries such as Norway, Denmark and Finland, where the founder effect was determined, LGMD2A is the most frequent type of LGMD worldwide, followed either by dysferlinopathies in some areas or by sarcoglycanopthies in others (Fig. 1).